Reported 3 days ago
The article discusses two undervalued stocks in the pharmaceutical sector, CRISPR Therapeutics and Merck, both of which have seen significant declines in their share prices recently. CRISPR Therapeutics has a promising gene-editing therapy, Casgevy, that is not yet generating substantial revenue but has a vast market potential. Merck, despite facing competition to its leading drug Keytruda, continues to perform well with strong revenue and a solid pipeline of new treatments. Both stocks present potential long-term investment opportunities for patient investors.
Source: YAHOO